Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) has entered a securities purchase agreement with two institutional investors for the sale of 4,437,870 shares of common stock at $3.38 per share, aiming for gross proceeds of approximately $15 million. The offering, scheduled to close around January 15, 2021, is executed under a shelf registration statement effective since September 23, 2020. Ladenburg Thalmann acts as the exclusive placement agent. The funds will be used to support the company's development of plant-based medicines for GI distress, specifically targeting chronic diarrhea.
Positive
- Gross proceeds of approximately $15 million to bolster business development.
- Offering priced above market, indicating investor confidence.
Negative
- Potential shareholder dilution due to the issuance of new shares.
News Market Reaction – JAGX
On the day this news was published, JAGX gained 9.17%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870 shares of common stock at a purchase price of
Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the offering.
The closing of the offering is expected to take place on or about January 15, 2021, subject to the satisfaction or waiver of customary closing conditions.
The shares of common stock described above are being offered pursuant to a "shelf" registration statement on Form S-3 (File No. 333-248763) that was filed by the Company with the Securities and Exchange Commission (SEC) and was declared effective on September 23, 2020. The Company will file a prospectus supplement with the SEC relating to such shares of common stock. Copies of the prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering may be obtained on the SEC's website located at http://www.sec.gov, when available, or from Ladenburg Thalmann & Co. Inc., 277 Park Avenue, 26th Floor, New York, NY 10172, or by email at prospectus@ladenburg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit napopharma.com.
About Mytesi®
Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (
See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the expectation that the offering will close on or about January 15, 2021 and use of proceeds. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/624108/Jaguar-Health-Announces-15-Million-Registered-Direct-Offering-Priced-Above-the-Market-Under-Nasdaq-Rules
FAQ
What is the amount raised in Jaguar Health's recent offering?
When is the closing date for the securities offering?
Who are the investors in Jaguar Health's offering?
What will Jaguar Health do with the proceeds from the offering?
How might the offering affect shareholders of Jaguar Health (JAGX)?
